CPPC's Policy Framework is built on three pillars. This post takes a closer look at the second: promoting evidence-based, balanced regulation, and why the way policy gets made matters just as much as the policy itself.
A new diagnostic test can take years to move from a research lab to a doctor's office, even after it has been shown to work. Somewhere in that gap, real patients are waiting for a tool that could change how their condition is caught or treated.
Regulation exists for good reason. Patients deserve to know that the devices and diagnostics they rely on are safe and effective. But there is a difference between rigorous review and unnecessary delay. When regulatory processes duplicate each other, or when decisions are shaped by politics or unsubstantiated concerns rather than clinical evidence, patients pay the price in lost time.
The goal is not less oversight. It is better oversight, grounded firmly in science and clinical data. Federal and state policymakers face real choices about how to structure review processes, and those choices should be measured against one standard: does this protect patients without choking off the innovations they need?
Balanced regulation does both at once. It keeps unsafe products off the market while making sure that safe, effective technologies reach patients without needless friction. It resists pressure to base decisions on assumptions rather than data. And it recognizes that every unnecessary delay is not a neutral outcome. It is a missed opportunity for someone waiting on the other side of that decision.
The Coalition to Protect Patient Care believes regulatory decisions affecting medical technology should be grounded in science and clinical evidence, not politics. We will continue to make the case for standards that are rigorous where rigor is needed and efficient where efficiency serves patients.
Good regulation does not have to stand in the way of access. Done right, it is what makes access possible and safe. That is the balance we are working to protect.